Ascendia
Pharmaceuticals, 661 Hwy 1st, North Brunswick, New Jersey, 08902, United States, 11-50 Employees
Phone Number: 17*********
Who is ASCENDIA
Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of e...
Read More
-
Headquarters: 661 Hwy 1st, North Brunswick, New Jersey, 08902, United States
-
Date Founded: 2012
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Jim Huang
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
Ascendia Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ascendia
Answer: Ascendia's headquarters are located at 661 Hwy 1st, North Brunswick, New Jersey, 08902, United States
Answer: Ascendia's phone number is 17*********
Answer: Ascendia's official website is https://ascendiapharma.com
Answer: Ascendia's revenue is $10 Million to $25 Million
Answer: Ascendia's SIC: 2834
Answer: Ascendia has 11-50 employees
Answer: Ascendia is in Pharmaceuticals
Answer: Ascendia contact info: Phone number: 17********* Website: https://ascendiapharma.com
Answer: Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies Rapid development through Phase I CTM materials for oral and parenteral dosage forms Fast discovery formulation support Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: Formulations for poorly soluble and low bioavailability drugs First-in-man injectable formulations Nano-emulsion and nano-particle formulations Peptide formulations Sustained release by parenteral or oral routes Development of 505(b)(2) products Development of complex generics High potency and DEA controlled drug substances Ocular formulation development Animal health formulations
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month